Drugs / CT7439
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06600789 | Aug 2024 → Apr 2026 overdue | cancer | Carrick Therapeutics Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-09-07 | Carrick Therapeutics Limited | Regulatory Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13 carricktherapeutics.com ↗
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-23 | Carrick Therapeutics Limited | Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) carricktherapeutics.com ↗ |
| 2023-09-07 | Carrick Therapeutics Limited | Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13 carricktherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT7439 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06600789 ↗ |
| Known as | CT7439 Capsules | “Drug: CT7439 Capsules (0.5 mg, 1mg, 3mg)” NCT06600789 ↗ |
| Route | Oral | “CT7439 capsules administered by mouth once a day” NCT06600789 ↗ |